BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: González-Reyes S, Marín L, González L, González LO, del Casar JM, Lamelas ML, González-Quintana JM, Vizoso FJ. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer. 2010;10:665. [PMID: 21129170 DOI: 10.1186/1471-2407-10-665] [Cited by in Crossref: 131] [Cited by in F6Publishing: 136] [Article Influence: 10.9] [Reference Citation Analysis]
Number Citing Articles
1 Duan H, Qu L, Shou C. Mycoplasma hyorhinis induces epithelial-mesenchymal transition in gastric cancer cell MGC803 via TLR4-NF-κB signaling. Cancer Lett 2014;354:447-54. [PMID: 25149064 DOI: 10.1016/j.canlet.2014.08.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
2 Florea ID, Karaoulani C. Epigenetic Changes of the Immune System with Role in Tumor Development. Methods Mol Biol 2018;1856:203-18. [PMID: 30178253 DOI: 10.1007/978-1-4939-8751-1_11] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
3 Luddy KA, Robertson-Tessi M, Tafreshi NK, Soliman H, Morse DL. The role of toll-like receptors in colorectal cancer progression: evidence for epithelial to leucocytic transition. Front Immunol 2014;5:429. [PMID: 25368611 DOI: 10.3389/fimmu.2014.00429] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
4 Tashireva LA, Perelmuter VM, Manskikh VN, Denisov EV, Savelieva OE, Kaygorodova EV, Zavyalova MV. Types of Immune-Inflammatory Responses as a Reflection of Cell-Cell Interactions under Conditions of Tissue Regeneration and Tumor Growth. Biochemistry (Mosc) 2017;82:542-55. [PMID: 28601064 DOI: 10.1134/S0006297917050029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
5 Eiro N, Gonzalez LO, Fraile M, Cid S, Schneider J, Vizoso FJ. Breast Cancer Tumor Stroma: Cellular Components, Phenotypic Heterogeneity, Intercellular Communication, Prognostic Implications and Therapeutic Opportunities. Cancers (Basel) 2019;11:E664. [PMID: 31086100 DOI: 10.3390/cancers11050664] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 11.0] [Reference Citation Analysis]
6 Angrini M, Varthaman A, Cremer I. Toll-Like Receptors (TLRs) in the Tumor Microenvironment (TME): A Dragon-Like Weapon in a Non-fantasy Game of Thrones. In: Birbrair A, editor. Tumor Microenvironment. Cham: Springer International Publishing; 2020. pp. 145-73. [DOI: 10.1007/978-3-030-44518-8_9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Zhou J, Chen X, Gilvary DL, Tejera MM, Eksioglu EA, Wei S, Djeu JY. HMGB1 induction of clusterin creates a chemoresistant niche in human prostate tumor cells. Sci Rep 2015;5:15085. [PMID: 26469759 DOI: 10.1038/srep15085] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
8 Wang CH, Wang PJ, Hsieh YC, Lo S, Lee YC, Chen YC, Tsai CH, Chiu WC, Chu-Sung Hu S, Lu CW, Yang YF, Chiu CC, Ou-Yang F, Wang YM, Hou MF, Yuan SS. Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness properties. Oncogene 2018;37:589-600. [PMID: 28991224 DOI: 10.1038/onc.2017.357] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 8.8] [Reference Citation Analysis]
9 Saponaro C, Scarpi E, Sonnessa M, Cioffi A, Buccino F, Giotta F, Pastena MI, Zito FA, Mangia A. Prognostic Value of NLRP3 Inflammasome and TLR4 Expression in Breast Cancer Patients. Front Oncol 2021;11:705331. [PMID: 34540671 DOI: 10.3389/fonc.2021.705331] [Reference Citation Analysis]
10 Kang Y, Su G, Sun J, Zhang Y. Activation of the TLR4/MyD88 signaling pathway contributes to the development of human hepatocellular carcinoma via upregulation of IL-23 and IL-17A. Oncol Lett 2018;15:9647-54. [PMID: 29928340 DOI: 10.3892/ol.2018.8586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
11 Liu R, Luo F, Liu X, Wang L, Yang J, Deng Y, Huang E, Qian J, Lu Z, Jiang X, Zhang D, Chu Y. Biological Response Modifier in Cancer Immunotherapy. Adv Exp Med Biol 2016;909:69-138. [PMID: 27240457 DOI: 10.1007/978-94-017-7555-7_2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
12 Zidi S, Sghaier I, Gazouani E, Mezlini A, Yacoubi-Loueslati B. Evaluation of Toll-Like Receptors 2/3/4/9 Gene Polymorphisms in Cervical Cancer Evolution. Pathol Oncol Res. 2016;22:323-330. [PMID: 26548749 DOI: 10.1007/s12253-015-0009-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
13 Ehsan N, Murad S, Ashiq T, Mansoor MU, Gul S, Khalid S, Younas M. Significant correlation of TLR4 expression with the clinicopathological features of invasive ductal carcinoma of the breast. Tumour Biol 2013;34:1053-9. [PMID: 23338716 DOI: 10.1007/s13277-013-0645-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
14 Eiró N, Altadill A, Juárez LM, Rodríguez M, González LO, Atienza S, Bermúdez S, Fernandez-Garcia B, Fresno-Forcelledo MF, Rodrigo L. Toll-like receptors 3, 4 and 9 in hepatocellular carcinoma: Relationship with clinicopathological characteristics and prognosis. Hepatol Res. 2014;44:769-778. [PMID: 23742263 DOI: 10.1111/hepr.12180] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
15 Sudan SK, Deshmukh SK, Poosarla T, Holliday NP, Dyess DL, Singh AP, Singh S. Resistin: An inflammatory cytokine with multi-faceted roles in cancer. Biochim Biophys Acta Rev Cancer. 2020;1874:188419. [PMID: 32822824 DOI: 10.1016/j.bbcan.2020.188419] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
16 Ni YH, Ding L, Zhang DY, Hou YY, Huang X, Hu Q. Distinct expression patterns of Toll-like receptor 7 in tumour cells and fibroblast-like cells in oral squamous cell carcinoma. Histopathology 2015;67:730-9. [DOI: 10.1111/his.12703] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
17 Mokhtari Y, Pourbagheri-Sigaroodi A, Zafari P, Bagheri N, Ghaffari SH, Bashash D. Toll-like receptors (TLRs): An old family of immune receptors with a new face in cancer pathogenesis. J Cell Mol Med 2021;25:639-51. [PMID: 33336901 DOI: 10.1111/jcmm.16214] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Zhao Y, Kong X, Li X, Yan S, Yuan C, Hu W, Yang Q. Metadherin mediates lipopolysaccharide-induced migration and invasion of breast cancer cells. PLoS One 2011;6:e29363. [PMID: 22195048 DOI: 10.1371/journal.pone.0029363] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
19 Wang Q, Zhang X, Xiao T, Pan C, Liu X, Zhao Y. Prognostic role of Toll-like receptors in cancer: a meta-analysis. Ther Clin Risk Manag 2018;14:1323-30. [PMID: 30104878 DOI: 10.2147/TCRM.S171341] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
20 Yusuf N. Toll-like receptor mediated regulation of breast cancer: a case of mixed blessings. Front Immunol 2014;5:224. [PMID: 24904578 DOI: 10.3389/fimmu.2014.00224] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
21 Zandi Z, Kashani B, Bashash D, Poursani EM, Mousavi SA, Chahardoli B, Ghaffari SH. The anticancer effect of the TLR4 inhibition using TAK‐242 (resatorvid) either as a single agent or in combination with chemotherapy: A novel therapeutic potential for breast cancer. J Cell Biochem 2020;121:1623-34. [DOI: 10.1002/jcb.29397] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
22 Ridge SM, Sullivan FJ, Glynn SA. Mesenchymal stem cells: key players in cancer progression. Mol Cancer. 2017;16:31. [PMID: 28148268 DOI: 10.1186/s12943-017-0597-8] [Cited by in Crossref: 209] [Cited by in F6Publishing: 208] [Article Influence: 41.8] [Reference Citation Analysis]
23 Yeh DW, Huang LR, Chen YW, Huang CF, Chuang TH. Interplay between Inflammation and Stemness in Cancer Cells: The Role of Toll-Like Receptor Signaling. J Immunol Res 2016;2016:4368101. [PMID: 28116318 DOI: 10.1155/2016/4368101] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
24 Volk-Draper L, Hall K, Griggs C, Rajput S, Kohio P, DeNardo D, Ran S. Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner. Cancer Res 2014;74:5421-34. [PMID: 25274031 DOI: 10.1158/0008-5472.CAN-14-0067] [Cited by in Crossref: 127] [Cited by in F6Publishing: 76] [Article Influence: 18.1] [Reference Citation Analysis]
25 Fernandez-Garcia B, Eiró N, Marín L, González-Reyes S, González LO, Lamelas ML, Vizoso FJ. Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis. Histopathology 2014;64:512-22. [PMID: 24117661 DOI: 10.1111/his.12300] [Cited by in Crossref: 91] [Cited by in F6Publishing: 92] [Article Influence: 10.1] [Reference Citation Analysis]
26 Truong AD, Hong YH, Lillehoj HS. RNA-seq Profiles of Immune Related Genes in the Spleen of Necrotic Enteritis-afflicted Chicken Lines. Asian-Australas J Anim Sci 2015;28:1496-511. [PMID: 26323406 DOI: 10.5713/ajas.15.0143] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
27 Ma X, Wang H, Zhang P, Xu L, Tian Z. Association between small intestinal bacterial overgrowth and toll-like receptor 4 in patients with pancreatic carcinoma and cholangiocarcinoma. Turk J Gastroenterol 2019;30:177-83. [PMID: 30457560 DOI: 10.5152/tjg.2018.17512] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
28 Zeljic K, Supic G, Jovic N, Kozomara R, Brankovic‐magic M, Obrenovic M, Magic Z. Association of TLR2, TLR3, TLR4 and CD14 genes polymorphisms with oral cancer risk and survival. Oral Dis 2014;20:416-24. [DOI: 10.1111/odi.12144] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
29 Farnebo L, Shahangian A, Lee Y, Shin JH, Scheeren FA, Sunwoo JB. Targeting Toll-like receptor 2 inhibits growth of head and neck squamous cell carcinoma. Oncotarget 2015;6:9897-907. [PMID: 25846753 DOI: 10.18632/oncotarget.3393] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
30 Yang H, Wang B, Wang T, Xu L, He C, Wen H, Yan J, Su H, Zhu X. Toll-like receptor 4 prompts human breast cancer cells invasiveness via lipopolysaccharide stimulation and is overexpressed in patients with lymph node metastasis. PLoS One 2014;9:e109980. [PMID: 25299052 DOI: 10.1371/journal.pone.0109980] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 9.1] [Reference Citation Analysis]
31 Rossi AH, Farias A, Fernández JE, Bonomi HR, Goldbaum FA, Berguer PM. Brucella spp. Lumazine Synthase Induces a TLR4-Mediated Protective Response against B16 Melanoma in Mice. PLoS One 2015;10:e0126827. [PMID: 25973756 DOI: 10.1371/journal.pone.0126827] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
32 Kartikasari AER, Prakash MD, Cox M, Wilson K, Boer JC, Cauchi JA, Plebanski M. Therapeutic Cancer Vaccines-T Cell Responses and Epigenetic Modulation. Front Immunol 2018;9:3109. [PMID: 30740111 DOI: 10.3389/fimmu.2018.03109] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
33 Guney Eskiler G, Deveci Özkan A. The relationship between the efficacy of talazoparib and the functional toll-like receptors 3 and 9 in triple negative breast cancer. Mol Immunol 2021;141:280-6. [PMID: 34906906 DOI: 10.1016/j.molimm.2021.12.007] [Reference Citation Analysis]
34 Tuomela J, Sandholm J, Kaakinen M, Patel A, Kauppila JH, Ilvesaro J, Chen D, Harris KW, Graves D, Selander KS. DNA from dead cancer cells induces TLR9-mediated invasion and inflammation in living cancer cells. Breast Cancer Res Treat 2013;142:477-87. [PMID: 24212717 DOI: 10.1007/s10549-013-2762-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
35 Ran S. The Role of TLR4 in Chemotherapy-Driven Metastasis. Cancer Res. 2015;75:2405-2410. [PMID: 25998620 DOI: 10.1158/0008-5472.can-14-3525] [Cited by in Crossref: 67] [Cited by in F6Publishing: 28] [Article Influence: 9.6] [Reference Citation Analysis]
36 Chrétien S, Zerdes I, Bergh J, Matikas A, Foukakis T. Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy. Cancers (Basel) 2019;11:E628. [PMID: 31060337 DOI: 10.3390/cancers11050628] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
37 Eiró N, Ovies C, Fernandez-Garcia B, Álvarez-Cuesta CC, González L, González LO, Vizoso FJ. Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma: relationship with clinicopathological characteristics and prognosis. Arch Dermatol Res 2013;305:59-67. [PMID: 23179584 DOI: 10.1007/s00403-012-1300-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
38 Green TL, Cruse JM, Lewis RE, Craft BS. Circulating tumor cells (CTCs) from metastatic breast cancer patients linked to decreased immune function and response to treatment. Exp Mol Pathol 2013;95:174-9. [PMID: 23831428 DOI: 10.1016/j.yexmp.2013.06.013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
39 Beilmann-Lehtonen I, Böckelman C, Mustonen H, Koskensalo S, Hagström J, Haglund C. The prognostic role of tissue TLR2 and TLR4 in colorectal cancer. Virchows Arch 2020;477:705-15. [PMID: 32424768 DOI: 10.1007/s00428-020-02833-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
40 Matijevic T, Pavelic J. The dual role of TLR3 in metastatic cell line. Clin Exp Metastasis 2011;28:701-12. [PMID: 21735101 DOI: 10.1007/s10585-011-9402-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
41 Singh A, Devkar R, Basu A. Myeloid Differentiation Primary Response 88-Cyclin D1 Signaling in Breast Cancer Cells Regulates Toll-Like Receptor 3-Mediated Cell Proliferation. Front Oncol 2020;10:1780. [PMID: 33072559 DOI: 10.3389/fonc.2020.01780] [Reference Citation Analysis]
42 Goutagny N, Estornes Y, Hasan U, Lebecque S, Caux C. Targeting pattern recognition receptors in cancer immunotherapy. Target Oncol 2012;7:29-54. [PMID: 22399234 DOI: 10.1007/s11523-012-0213-1] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 6.5] [Reference Citation Analysis]
43 Bianchi F, Pretto S, Tagliabue E, Balsari A, Sfondrini L. Exploiting poly(I:C) to induce cancer cell apoptosis. Cancer Biol Ther 2017;18:747-56. [PMID: 28881163 DOI: 10.1080/15384047.2017.1373220] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 9.2] [Reference Citation Analysis]
44 Kuo SM, Burl LR, Hu Z. Cellular phenotype-dependent and -independent effects of vitamin C on the renewal and gene expression of mouse embryonic fibroblasts. PLoS One 2012;7:e32957. [PMID: 22427916 DOI: 10.1371/journal.pone.0032957] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
45 Chen DN, Song CG, Yu KD, Jiang YZ, Ye FG, Shao ZM. A Prospective Evaluation of the Association between a Single Nucleotide Polymorphism rs3775291 in Toll-Like Receptor 3 and Breast Cancer Relapse. PLoS One 2015;10:e0133184. [PMID: 26226228 DOI: 10.1371/journal.pone.0133184] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
46 Hu J, Xu J, Feng X, Li Y, Hua F, Xu G. Differential Expression of the TLR4 Gene in Pan-Cancer and Its Related Mechanism. Front Cell Dev Biol 2021;9:700661. [PMID: 34631699 DOI: 10.3389/fcell.2021.700661] [Reference Citation Analysis]
47 Feng Y, Chen Y, Meng Y, Cao Q, Liu Q, Ling C, Wang C. Bufalin Suppresses Migration and Invasion of Hepatocellular Carcinoma Cells Elicited by Poly (I:C) Therapy. Oncoimmunology 2018;7:e1426434. [PMID: 29721392 DOI: 10.1080/2162402X.2018.1426434] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
48 Khademalhosseini M, Arababadi MK. Toll-like receptor 4 and breast cancer: an updated systematic review. Breast Cancer 2019;26:265-71. [PMID: 30543015 DOI: 10.1007/s12282-018-00935-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
49 Eiro N, Carrión JF, Cid S, Andicoechea A, García-Muñiz JL, González LO, Vizoso FJ. Toll-Like Receptor 4 and Matrix Metalloproteases 11 and 13 as Predictors of Tumor Recurrence and Survival in Stage II Colorectal Cancer. Pathol Oncol Res 2019;25:1589-97. [PMID: 30710321 DOI: 10.1007/s12253-019-00611-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
50 Sandholm J, Kauppila JH, Pressey C, Tuomela J, Jukkola-Vuorinen A, Vaarala M, Johnson MR, Harris KW, Selander KS. Estrogen receptor-α and sex steroid hormones regulate Toll-like receptor-9 expression and invasive function in human breast cancer cells. Breast Cancer Res Treat 2012;132:411-9. [PMID: 21607583 DOI: 10.1007/s10549-011-1590-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
51 Gruffaz M, Vasan K, Tan B, Ramos da Silva S, Gao SJ. TLR4-Mediated Inflammation Promotes KSHV-Induced Cellular Transformation and Tumorigenesis by Activating the STAT3 Pathway. Cancer Res 2017;77:7094-108. [PMID: 29051178 DOI: 10.1158/0008-5472.CAN-17-2321] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
52 Gharbavi M, Sharafi A, Ghanbarzadeh S. Mesenchymal Stem Cells: A New Generation of Therapeutic Agents as Vehicles in Gene Therapy. Curr Gene Ther 2020;20:269-84. [PMID: 32515309 DOI: 10.2174/1566523220666200607190339] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Grimmig T, Moench R, Kreckel J, Haack S, Rueckert F, Rehder R, Tripathi S, Ribas C, Chandraker A, Germer CT, Gasser M, Waaga-Gasser AM. Toll Like Receptor 2, 4, and 9 Signaling Promotes Autoregulative Tumor Cell Growth and VEGF/PDGF Expression in Human Pancreatic Cancer. Int J Mol Sci 2016;17:E2060. [PMID: 27941651 DOI: 10.3390/ijms17122060] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
54 Bhatelia K, Singh K, Singh R. TLRs: linking inflammation and breast cancer. Cell Signal 2014;26:2350-7. [PMID: 25093807 DOI: 10.1016/j.cellsig.2014.07.035] [Cited by in Crossref: 97] [Cited by in F6Publishing: 106] [Article Influence: 12.1] [Reference Citation Analysis]
55 Eiró N, González-Reyes S, González L, González LO, Altadill A, Andicoechea A, Fresno-Forcelledo MF, Rodrigo-Sáez L, Vizoso FJ. Duodenal expression of Toll-like receptors and interleukins are increased in both children and adult celiac patients. Dig Dis Sci 2012;57:2278-85. [PMID: 22562536 DOI: 10.1007/s10620-012-2184-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
56 Luo Q, Hu S, Yan M, Sun Z, Chen W, Chen F. Activation of Toll-like receptor 3 induces apoptosis of oral squamous carcinoma cells in vitro and in vivo. Int J Biochem Cell Biol 2012;44:1266-75. [PMID: 22568929 DOI: 10.1016/j.biocel.2012.04.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
57 Nihon-Yanagi Y, Wakayama M, Tochigi N, Saito F, Ogata H, Shibuya K. Immunohistochemical Analysis of Toll-Like Receptors, MyD88, and TRIF in Human Papillary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma. J Thyroid Res 2021;2021:4226491. [PMID: 34306609 DOI: 10.1155/2021/4226491] [Reference Citation Analysis]
58 Obeid E, Nanda R, Fu YX, Olopade OI. The role of tumor-associated macrophages in breast cancer progression (review). Int J Oncol. 2013;43:5-12. [PMID: 23673510 DOI: 10.3892/ijo.2013.1938] [Cited by in Crossref: 116] [Cited by in F6Publishing: 116] [Article Influence: 12.9] [Reference Citation Analysis]
59 Sandholm J, Selander KS. Toll-like receptor 9 in breast cancer. Front Immunol 2014;5:330. [PMID: 25101078 DOI: 10.3389/fimmu.2014.00330] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
60 Gao C, Qiao T, Zhang B, Yuan S, Zhuang X, Luo Y. TLR9 signaling activation at different stages in colorectal cancer and NF-kappaB expression. Onco Targets Ther 2018;11:5963-71. [PMID: 30271180 DOI: 10.2147/OTT.S174274] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
61 Klein JC, Moses K, Zelinskyy G, Sody S, Buer J, Lang S, Helfrich I, Dittmer U, Kirschning CJ, Brandau S. Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growth. Nat Commun 2017;8:14600. [PMID: 28300057 DOI: 10.1038/ncomms14600] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
62 Zhang M, Yan Z, Wang J, Yao X. Toll-like receptors 7 and 8 expression correlates with the expression of immune biomarkers and positively predicts the clinical outcome of patients with melanoma. Onco Targets Ther 2017;10:4339-46. [PMID: 28919783 DOI: 10.2147/OTT.S136194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
63 Petricevic B, Vrbanec D, Jakic-Razumovic J, Brcic I, Rabic D, Badovinac T, Ozimec E, Bali V. Expression of Toll-like receptor 4 and beta 1 integrin in breast cancer. Med Oncol 2012;29:486-94. [PMID: 21400218 DOI: 10.1007/s12032-011-9885-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
64 Bhattacharya D, Yusuf N. Expression of toll-like receptors on breast tumors: taking a toll on tumor microenvironment. Int J Breast Cancer 2012;2012:716564. [PMID: 22295250 DOI: 10.1155/2012/716564] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
65 Grimmig T, Gasser M, Moench R, Zhu LJ, Nawalaniec K, Callies S, Wagner M, Polat B, Mothi SS, Luo Y, Ribas CM, Malafaia O, Hsiao LL, Waaga-Gasser AM. Expression of Tumor-mediated CD137 ligand in human colon cancer indicates dual signaling effects. Oncoimmunology 2019;8:e1651622. [PMID: 31741755 DOI: 10.1080/2162402X.2019.1651622] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
66 Mishra V, Pathak C. Human Toll-Like Receptor 4 (hTLR4): Structural and functional dynamics in cancer. International Journal of Biological Macromolecules 2019;122:425-51. [DOI: 10.1016/j.ijbiomac.2018.10.142] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
67 Baakhlagh S, Kashani B, Zandi Z, Bashash D, Moradkhani M, Nasrollahzadeh A, Yaghmaei M, Mousavi SA, Ghaffari SH. Toll-like receptor 4 signaling pathway is correlated with pathophysiological characteristics of AML patients and its inhibition using TAK-242 suppresses AML cell proliferation. Int Immunopharmacol 2021;90:107202. [PMID: 33278749 DOI: 10.1016/j.intimp.2020.107202] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 Basith S, Manavalan B, Yoo TH, Kim SG, Choi S. Roles of toll-like receptors in cancer: a double-edged sword for defense and offense. Arch Pharm Res. 2012;35:1297-1316. [PMID: 22941474 DOI: 10.1007/s12272-012-0802-7] [Cited by in Crossref: 117] [Cited by in F6Publishing: 114] [Article Influence: 11.7] [Reference Citation Analysis]
69 Resler AJ, Malone KE, Johnson LG, Malkki M, Petersdorf EW, McKnight B, Madeleine MM. Genetic variation in TLR or NFkappaB pathways and the risk of breast cancer: a case-control study. BMC Cancer 2013;13:219. [PMID: 23634849 DOI: 10.1186/1471-2407-13-219] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
70 Takada K, Komine-Aizawa S, Hirohata N, Trinh QD, Nishina A, Kimura H, Hayakawa S. Poly I:C induces collective migration of HaCaT keratinocytes via IL-8. BMC Immunol 2017;18:19. [PMID: 28438134 DOI: 10.1186/s12865-017-0202-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
71 Zheng S, Fu W, Ma R, Huang Q, Gu J, Zhou J, Lu K, Guo G. Suppression of MD2 inhibits breast cancer in vitro and in vivo. Clin Transl Oncol 2021;23:1811-7. [PMID: 33733435 DOI: 10.1007/s12094-021-02587-9] [Reference Citation Analysis]
72 Balamurugan K, Sharan S, Klarmann KD, Zhang Y, Coppola V, Summers GH, Roger T, Morrison DK, Keller JR, Sterneck E. FBXW7α attenuates inflammatory signalling by downregulating C/EBPδ and its target gene Tlr4. Nat Commun 2013;4:1662. [PMID: 23575666 DOI: 10.1038/ncomms2677] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 5.7] [Reference Citation Analysis]
73 Khatami M. Is cancer a severe delayed hypersensitivity reaction and histamine a blueprint? Clin Transl Med 2016;5:35. [PMID: 27558401 DOI: 10.1186/s40169-016-0108-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
74 Chuang HC, Huang CC, Chien CY, Chuang JH. Toll-like receptor 3-mediated tumor invasion in head and neck cancer. Oral Oncol 2012;48:226-32. [PMID: 22070917 DOI: 10.1016/j.oraloncology.2011.10.008] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
75 Hübbe ML, Jæhger DE, Andresen TL, Andersen MH. Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade. Front Immunol 2020;11:578349. [PMID: 33101304 DOI: 10.3389/fimmu.2020.578349] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Kidd LC, Rogers EN, Yeyeodu ST, Jones DZ, Kimbro KS. Contribution of toll-like receptor signaling pathways to breast tumorigenesis and treatment. Breast Cancer (Dove Med Press) 2013;5:43-51. [PMID: 24648757 DOI: 10.2147/BCTT.S29172] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
77 Shi S, Xu C, Fang X, Zhang Y, Li H, Wen W, Yang G. Expression profile of Toll‑like receptors in human breast cancer. Mol Med Rep 2020;21:786-94. [PMID: 31789409 DOI: 10.3892/mmr.2019.10853] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
78 He Z, Huang X, Ni Y, Shi P, Wang Z, Han W, Hu Q. Functional toll-like receptor 3 expressed by oral squamous cell carcinoma induced cell apoptosis and decreased migration. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 2014;118:92-100. [DOI: 10.1016/j.oooo.2014.03.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
79 Fűri I, Kalmár A, Wichmann B, Spisák S, Schöller A, Barták B, Tulassay Z, Molnár B. Cell Free DNA of Tumor Origin Induces a 'Metastatic' Expression Profile in HT-29 Cancer Cell Line. PLoS One 2015;10:e0131699. [PMID: 26133168 DOI: 10.1371/journal.pone.0131699] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
80 Theodoropoulos GE, Saridakis V, Karantanos T, Michalopoulos NV, Zagouri F, Kontogianni P, Lymperi M, Gazouli M, Zografos GC. Toll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer development. Breast. 2012;21:534-538. [PMID: 22560646 DOI: 10.1016/j.breast.2012.04.001] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 5.2] [Reference Citation Analysis]
81 Han JH, Park JH, Kim BY, Chang SN, Kim TH, Park JH, Kim DJ. Decreased expression of Toll-like receptor 4 and 5 during progression of prostate transformation in transgenic adenocarcinoma of mouse prostate mice. J Vet Sci 2015;16:281-7. [PMID: 25797291 DOI: 10.4142/jvs.2015.16.3.281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
82 Haricharan S, Brown P. TLR4 has a TP53-dependent dual role in regulating breast cancer cell growth. Proc Natl Acad Sci USA. 2015;112:E3216-E3225. [PMID: 26063617 DOI: 10.1073/pnas.1420811112] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.7] [Reference Citation Analysis]
83 Kedarinath K, Parks GD. Differential In Vitro Growth and Cell Killing of Cancer versus Benign Prostate Cells by Oncolytic Parainfluenza Virus. Pathogens 2022;11:493. [DOI: 10.3390/pathogens11050493] [Reference Citation Analysis]
84 Kashani B, Zandi Z, Karimzadeh MR, Bashash D, Nasrollahzadeh A, Ghaffari SH. Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers. Immunol Res 2019;67:505-16. [DOI: 10.1007/s12026-019-09113-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
85 Wang L, Zhu R, Huang Z, Li H, Zhu H. Lipopolysaccharide-induced toll-like receptor 4 signaling in cancer cells promotes cell survival and proliferation in hepatocellular carcinoma. Dig Dis Sci. 2013;58:2223-2236. [PMID: 23828139 DOI: 10.1007/s10620-013-2745-3] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 5.8] [Reference Citation Analysis]
86 Li X, Guo D, Chen Y, Hu Y, Yokota S. Toll-Like Receptors/TNF-α Pathway Crosstalk and Impact on Different Sites of Recurrent Myocardial Infarction in Elderly Patients. BioMed Research International 2022;2022:1-11. [DOI: 10.1155/2022/1280350] [Reference Citation Analysis]
87 Khan A, Khan Z, Warnakulasuriya S. Cancer-associated toll-like receptor modulation and insinuation in infection susceptibility: association or coincidence? Annals of Oncology 2016;27:984-97. [DOI: 10.1093/annonc/mdw053] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
88 Bayraktar R, Bertilaccio MTS, Calin GA. The Interaction Between Two Worlds: MicroRNAs and Toll-Like Receptors. Front Immunol 2019;10:1053. [PMID: 31139186 DOI: 10.3389/fimmu.2019.01053] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 15.3] [Reference Citation Analysis]
89 Oblak A, Jerala R. Toll-like receptor 4 activation in cancer progression and therapy. Clin Dev Immunol 2011;2011:609579. [PMID: 22110526 DOI: 10.1155/2011/609579] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 8.2] [Reference Citation Analysis]
90 Gallego-Jara J, Lozano-Terol G, Sola-Martínez RA, Cánovas-Díaz M, de Diego Puente T. A Compressive Review about Taxol®: History and Future Challenges. Molecules 2020;25:E5986. [PMID: 33348838 DOI: 10.3390/molecules25245986] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
91 Naqvi I, Giroux N, Olson L, Morrison SA, Llanga T, Akinade TO, Zhu Y, Zhong Y, Bose S, Arvai S, Abramson K, Chen L, Que L, Kraft B, Shen X, Lee J, Leong KW, Nair SK, Sullenger B. DAMPs/PAMPs induce monocytic TLR activation and tolerance in COVID-19 patients; nucleic acid binding scavengers can counteract such TLR agonists. Biomaterials 2022;283:121393. [DOI: 10.1016/j.biomaterials.2022.121393] [Reference Citation Analysis]
92 Xu QQ, Zhou Q, Xu LL, Lin H, Wang XJ, Ma WL, Zhai K, Tong ZH, Su Y, Shi HZ. Toll-like receptor 4 signaling inhibits malignant pleural effusion by altering Th1/Th17 responses. Cell Biol Int 2015;39:1120-30. [PMID: 25939739 DOI: 10.1002/cbin.10485] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
93 Moumad K, Lascorz J, Bevier M, Khyatti M, Ennaji MM, Benider A, Huhn S, Lu S, Chouchane L, Corbex M, Hemminki K, Försti A. Genetic polymorphisms in host innate immune sensor genes and the risk of nasopharyngeal carcinoma in North Africa. G3 (Bethesda) 2013;3:971-7. [PMID: 23576520 DOI: 10.1534/g3.112.005371] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
94 Jia D, Wang L. The other face of TLR3: A driving force of breast cancer stem cells. Mol Cell Oncol 2015;2:e981443. [PMID: 27308515 DOI: 10.4161/23723556.2014.981443] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
95 Ronkainen H, Hirvikoski P, Kauppila S, Vuopala KS, Paavonen TK, Selander KS, Vaarala MH. Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma. J Exp Clin Cancer Res 2011;30:84. [PMID: 21929816 DOI: 10.1186/1756-9966-30-84] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
96 Eiró N, Pidal I, Fernandez-Garcia B, Junquera S, Lamelas ML, del Casar JM, González LO, López-Muñiz A, Vizoso FJ. Impact of CD68/(CD3+CD20) ratio at the invasive front of primary tumors on distant metastasis development in breast cancer. PLoS One 2012;7:e52796. [PMID: 23300781 DOI: 10.1371/journal.pone.0052796] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
97 Eiró N, Vizoso FJ. Inflammation and cancer. World J Gastrointest Surg 2012; 4(3): 62-72 [PMID: 22530080 DOI: 10.4240/wjgs.v4.i3.62] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 80] [Article Influence: 8.6] [Reference Citation Analysis]
98 Xu H, Wu Q, Dang S, Jin M, Xu J, Cheng Y, Pan M, Wu Y, Zhang C, Zhang Y. Alteration of CXCR7 expression mediated by TLR4 promotes tumor cell proliferation and migration in human colorectal carcinoma. PLoS One. 2011;6:e27399. [PMID: 22180778 DOI: 10.1371/journal.pone.0027399] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
99 Shawky MS, Ricciardelli C, Lord M, Whitelock J, Ferro V, Britt K, Thompson EW. Proteoglycans: Potential Agents in Mammographic Density and the Associated Breast Cancer Risk. J Mammary Gland Biol Neoplasia 2015;20:121-31. [PMID: 26501889 DOI: 10.1007/s10911-015-9346-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
100 Jones JO, Moody WM, Shields JD. Microenvironmental modulation of the developing tumour: an immune-stromal dialogue. Mol Oncol 2021;15:2600-33. [PMID: 32741067 DOI: 10.1002/1878-0261.12773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
101 Agupitan AD, Neeson P, Williams S, Howitt J, Haupt S, Haupt Y. P53: A Guardian of Immunity Becomes Its Saboteur through Mutation. Int J Mol Sci 2020;21:E3452. [PMID: 32414156 DOI: 10.3390/ijms21103452] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
102 Sheyhidin I, Nabi G, Hasim A, Zhang RP, Ainiwaer J, Ma H, Wang H. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol 2011; 17(32): 3745-3751 [PMID: 21990957 DOI: 10.3748/wjg.v17.i32.3745] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 64] [Article Influence: 6.2] [Reference Citation Analysis]
103 Ridnour LA, Cheng RY, Switzer CH, Heinecke JL, Ambs S, Glynn S, Young HA, Trinchieri G, Wink DA. Molecular pathways: toll-like receptors in the tumor microenvironment--poor prognosis or new therapeutic opportunity. Clin Cancer Res 2013;19:1340-6. [PMID: 23271799 DOI: 10.1158/1078-0432.CCR-12-0408] [Cited by in Crossref: 93] [Cited by in F6Publishing: 53] [Article Influence: 9.3] [Reference Citation Analysis]
104 Kim TW, Lee SJ, Oh BM, Lee H, Uhm TG, Min JK, Park YJ, Yoon SR, Kim BY, Kim JW. Epigenetic modification of TLR4 promotes activation of NF-κB by regulating methyl-CpG-binding domain protein 2 and Sp1 in gastric cancer. Oncotarget. 2015; Dec 10. [Epub ahead of print]. [PMID: 26675260 DOI: 10.18632/oncotarget.6549] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
105 Dworzanska A, Polz-dacewicz M. The role of Toll-like receptors (TLRs) in virus-related cancers: a mini review. Current Issues in Pharmacy and Medical Sciences 2020;33:225-7. [DOI: 10.2478/cipms-2020-0038] [Reference Citation Analysis]
106 Sato Y, Motoyama S, Wakita A, Kawakita Y, Liu J, Nagaki Y, Nanjo H, Ito S, Terata K, Imai K, Minamiya Y. High TLR4 expression predicts a poor prognosis after esophagectomy for advanced thoracic esophageal squamous cell carcinoma. Esophagus 2020;17:408-16. [PMID: 32170544 DOI: 10.1007/s10388-020-00732-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
107 Sun W, Ma X, Shen J, Yin F, Wang C, Cai Z. Bioinformatics analysis of differentially expressed pathways related to the metastatic characteristics of osteosarcoma. Int J Mol Med 2016;38:466-74. [PMID: 27353415 DOI: 10.3892/ijmm.2016.2657] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
108 Mai CW, Kang YB, Pichika MR. Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers. Onco Targets Ther 2013;6:1573-87. [PMID: 24235843 DOI: 10.2147/OTT.S50838] [Cited by in Crossref: 19] [Cited by in F6Publishing: 41] [Article Influence: 2.1] [Reference Citation Analysis]
109 Han S, Xu W, Wang Z, Qi X, Wang Y, Ni Y, Shen H, Hu Q, Han W. Crosstalk between the HIF-1 and Toll-like receptor/nuclear factor-κB pathways in the oral squamous cell carcinoma microenvironment. Oncotarget 2016;7:37773-89. [PMID: 27191981 DOI: 10.18632/oncotarget.9329] [Cited by in Crossref: 28] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
110 Bondhopadhyay B, Moirangthem A, Basu A. Innate adjuvant receptor Toll-like receptor 3 can promote breast cancer through cell surface. Tumour Biol 2015;36:1261-71. [PMID: 25348355 DOI: 10.1007/s13277-014-2737-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
111 Matijevic Glavan T, Cipak Gasparovic A, Vérillaud B, Busson P, Pavelic J. Toll-like receptor 3 stimulation triggers metabolic reprogramming in pharyngeal cancer cell line through Myc, MAPK, and HIF. Mol Carcinog 2017;56:1214-26. [PMID: 27805282 DOI: 10.1002/mc.22584] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
112 Yang C, Li C, Feng W. Toll-like receptor 4 genetic variants and prognosis of breast cancer: Toll-like receptor 4 gene polymorphisms and breast cancer. Tissue Antigens 2013;81:221-6. [DOI: 10.1111/tan.12096] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
113 Rajput S, Volk-Draper LD, Ran S. TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther. 2013;12:1676-1687. [PMID: 23720768 DOI: 10.1158/1535-7163.mct-12-1019] [Cited by in Crossref: 79] [Cited by in F6Publishing: 48] [Article Influence: 8.8] [Reference Citation Analysis]
114 Boufraqech M, Fassassi C, Kebebew E. TLR-10 polymorphism and papillary thyroid cancer: one more SNP to consider? Endocrine 2013;43:10-1. [PMID: 23138464 DOI: 10.1007/s12020-012-9827-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
115 Ahmad R, Al-Mass A, Atizado V, Al-Hubail A, Al-Ghimlas F, Al-Arouj M, Bennakhi A, Dermime S, Behbehani K. Elevated expression of the toll like receptors 2 and 4 in obese individuals: its significance for obesity-induced inflammation. J Inflamm (Lond) 2012;9:48. [PMID: 23191980 DOI: 10.1186/1476-9255-9-48] [Cited by in Crossref: 91] [Cited by in F6Publishing: 87] [Article Influence: 9.1] [Reference Citation Analysis]
116 Jing YY, Han ZP, Sun K, Zhang SS, Hou J, Liu Y, Li R, Gao L, Zhao X, Zhao QD. Toll-like receptor 4 signaling promotes epithelial-mesenchymal transition in human hepatocellular carcinoma induced by lipopolysaccharide. BMC Med. 2012;10:98. [PMID: 22938142 DOI: 10.1186/1741-7015-10-98] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 7.6] [Reference Citation Analysis]
117 Cen X, Liu S, Cheng K. The Role of Toll-Like Receptor in Inflammation and Tumor Immunity. Front Pharmacol 2018;9:878. [PMID: 30127747 DOI: 10.3389/fphar.2018.00878] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 14.3] [Reference Citation Analysis]
118 Ohadian Moghadam S, Nowroozi MR. Toll‐like receptors: The role in bladder cancer development, progression and immunotherapy. Scand J Immunol 2019;90. [DOI: 10.1111/sji.12818] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
119 Pandey N, Chauhan A, Jain N. TLR4 Polymorphisms and Expression in Solid Cancers. Mol Diagn Ther 2018;22:683-702. [PMID: 30311146 DOI: 10.1007/s40291-018-0361-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
120 Cheng D, Hao Y, Zhou W, Ma Y. Association between Toll-like receptor 3 polymorphisms and cancer risk: a meta-analysis. Tumour Biol 2014;35:7837-46. [PMID: 24819172 DOI: 10.1007/s13277-014-2049-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
121 Zheng X, Li S, Yang H. Roles of Toll-Like Receptor 3 in Human Tumors. Front Immunol 2021;12:667454. [PMID: 33986756 DOI: 10.3389/fimmu.2021.667454] [Reference Citation Analysis]
122 Szwajda A, Gautam P, Karhinen L, Jha SK, Saarela J, Shakyawar S, Turunen L, Yadav B, Tang J, Wennerberg K, Aittokallio T. Systematic Mapping of Kinase Addiction Combinations in Breast Cancer Cells by Integrating Drug Sensitivity and Selectivity Profiles. Chem Biol 2015;22:1144-55. [PMID: 26211361 DOI: 10.1016/j.chembiol.2015.06.021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
123 Bianchi F, Milione M, Casalini P, Centonze G, Le Noci VM, Storti C, Alexiadis S, Truini M, Sozzi G, Pastorino U, Balsari A, Tagliabue E, Sfondrini L. Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients. Sci Rep 2019;9:14288. [PMID: 31582772 DOI: 10.1038/s41598-019-50756-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
124 Ahmed A, Redmond HP, Wang JH. Links between Toll-like receptor 4 and breast cancer. Oncoimmunology 2013;2:e22945. [PMID: 23526132 DOI: 10.4161/onci.22945] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
125 Koliaraki V, Henriques A, Prados A, Kollias G. Unfolding innate mechanisms in the cancer microenvironment: The emerging role of the mesenchyme. J Exp Med 2020;217:e20190457. [PMID: 32044979 DOI: 10.1084/jem.20190457] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
126 Sootichote R, Thuwajit P, Singsuksawat E, Warnnissorn M, Yenchitsomanus PT, Ithimakin S, Chantharasamee J, Thuwajit C. Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8. BMC Cancer 2018;18:231. [PMID: 29486738 DOI: 10.1186/s12885-018-4155-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
127 Gowing SD, Cool-Lartigue JJ, Spicer JD, Seely AJE, Ferri LE. Toll-like receptors: exploring their potential connection with post-operative infectious complications and cancer recurrence. Clin Exp Metastasis 2020;37:225-39. [PMID: 31975313 DOI: 10.1007/s10585-020-10018-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
128 Klee NS, McCarthy CG, Martinez-Quinones P, Webb RC. Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy. Ther Adv Cardiovasc Dis 2017;11:297-317. [PMID: 28911261 DOI: 10.1177/1753944717729141] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
129 Yu L, Wang L, Chen S. Exogenous or endogenous Toll-like receptor ligands: which is the MVP in tumorigenesis? Cell Mol Life Sci 2012;69:935-49. [DOI: 10.1007/s00018-011-0864-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
130 Anunobi R, Boone BA, Cheh N, Tang D, Kang R, Loux T, Lotze MT, Zeh HJ. Extracellular DNA promotes colorectal tumor cell survival after cytotoxic chemotherapy. Journal of Surgical Research 2018;226:181-91. [DOI: 10.1016/j.jss.2018.02.042] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
131 Tarang S, Kumar S, Batra SK. Mucins and toll-like receptors: kith and kin in infection and cancer. Cancer Lett 2012;321:110-9. [PMID: 22306702 DOI: 10.1016/j.canlet.2012.01.040] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
132 Park GB, Jeong JY, Kim D. GLUT5 regulation by AKT1/3-miR-125b-5p downregulation induces migratory activity and drug resistance in TLR-modified colorectal cancer cells. Carcinogenesis 2020;41:1329-40. [PMID: 32649737 DOI: 10.1093/carcin/bgaa074] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
133 Holl EK, Frazier V, Landa K, Boczkowski D, Sullenger B, Nair SK. Controlling cancer-induced inflammation with a nucleic acid scavenger prevents lung metastasis in murine models of breast cancer. Mol Ther 2021;29:1772-81. [PMID: 33348055 DOI: 10.1016/j.ymthe.2020.12.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
134 Fox CR, Parks GD. Histone Deacetylase Inhibitors Enhance Cell Killing and Block Interferon-Beta Synthesis Elicited by Infection with an Oncolytic Parainfluenza Virus. Viruses 2019;11:E431. [PMID: 31083335 DOI: 10.3390/v11050431] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
135 Liu W, Jing Y, Yu G, Han Z, Yu D, Fan Q, Ye F, Li R, Gao L, Zhao Q, Wu M, Wei L. Toll like receptor 4 facilitates invasion and migration as a cancer stem cell marker in hepatocellular carcinoma. Cancer Letters 2015;358:136-43. [DOI: 10.1016/j.canlet.2014.12.019] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 8.4] [Reference Citation Analysis]
136 Sonnessa M, Cioffi A, Brunetti O, Silvestris N, Zito FA, Saponaro C, Mangia A. NLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer. Front Oncol 2020;10:1587. [PMID: 33014808 DOI: 10.3389/fonc.2020.01587] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
137 Tuomela J, Sandholm J, Karihtala P, Ilvesaro J, Vuopala KS, Kauppila JH, Kauppila S, Chen D, Pressey C, Härkönen P. Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer. Breast Cancer Res Treat. 2012;135:481-493. [PMID: 22847512 DOI: 10.1007/s10549-012-2181-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
138 Jia D, Yang W, Li L, Liu H, Tan Y, Ooi S, Chi L, Filion LG, Figeys D, Wang L. β-Catenin and NF-κB co-activation triggered by TLR3 stimulation facilitates stem cell-like phenotypes in breast cancer. Cell Death Differ 2015;22:298-310. [PMID: 25257174 DOI: 10.1038/cdd.2014.145] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 7.3] [Reference Citation Analysis]
139 Muresan XM, Bouchal J, Culig Z, Souček K. Toll-Like Receptor 3 in Solid Cancer and Therapy Resistance. Cancers (Basel) 2020;12:E3227. [PMID: 33147700 DOI: 10.3390/cancers12113227] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
140 Jiang N, Xie F, Chen L, Chen F, Sui L. The effect of TLR4 on the growth and local inflammatory microenvironment of HPV-related cervical cancer in vivo. Infect Agent Cancer 2020;15:12. [PMID: 32095158 DOI: 10.1186/s13027-020-0279-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
141 Wu TN, Chen HM, Shyur LF. Current Advancements of Plant-Derived Agents for Triple-Negative Breast Cancer Therapy through Deregulating Cancer Cell Functions and Reprogramming Tumor Microenvironment. Int J Mol Sci 2021;22:13571. [PMID: 34948368 DOI: 10.3390/ijms222413571] [Reference Citation Analysis]
142 Luo BP, Luo J, Hu YB, Yao XW, Wu FH. Cyclin D1b Splice Variant Promotes αvβ3-mediated EMT Induced by LPS in Breast Cancer Cells. Curr Med Sci 2018;38:467-72. [PMID: 30074214 DOI: 10.1007/s11596-018-1902-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]